Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer-Reference-Cited by-同舟云学术

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer

Published:2018-08-09 Issue:2 Volume:172 Page:371-379
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Borrie Adrienne E.,Rose Rhiannon V.,Choi Yun-Hee,Perera Francisco E.,Read Nancy,Sexton Tracy,Lock Michael,Vandenberg Theodore A.,Hahn Karin,Dinniwell Robert,Younus Jawaid,Logan Diane,Potvin Kylea,Yaremko Brian,Yu Edward,Lenehan John,Welch Stephen,Tyndale Rachel F.,Teft Wendy A.,Kim Richard B.^ORCID

Funder

Cancer Care Ontario

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-018-4910-z/fulltext.html

Reference22 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352

2. Mao JJ et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631–3639